MarketPulse

commercial traction

2 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Oncology Biotech Syndax Surges on $6.5M Investment Amid 629% Revenue Spike

Syndax Pharmaceuticals attracted $6.54M institutional investment as its approved cancer therapies generated $172.4M revenue, up 629% year-over-year, driving 80%+ stock surge.
SNDXrevenue growthcancer treatment
The Motley FoolThe Motley Fool··Eric Trie

Major Investor Exits Quantum Computing Inc. as Revenue Growth Remains Challenged

Major investor Anson Funds exits Quantum Computing Inc., liquidating 5.37M shares. Move signals investor concern over company's weak revenue growth and limited commercial traction.
NVDAQUBTMTCHquantum computingenterprise adoption